YKL-40 Polypeptides for Epithelial Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cosmetic and therapeutic compositions lack effective modulation of terminal epithelial differentiation and proteoglycan synthesis in the epidermis, leading to inadequate treatment of skin disorders related to aging, barrier function, and microorganism defense.
Innovation Solution
The use of YKL-40 polypeptides or their analogs, which are derived from the YKL-40 protein, to stimulate terminal epithelial differentiation and proteoglycan synthesis in the epidermis, either alone or in combination with other agents, to enhance skin health and defense mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cosmetic and therapeutic compositions are used, then general skin care is provided, but effective modulation of terminal epithelial differentiation and proteoglycan synthesis is lacking
Solution Approach 1:
The patent applies parameter changes by introducing YKL-40 polypeptides with specific amino acid sequences (SEQ ID NO: 5 and variants) that modulate terminal epithelial differentiation and proteoglycan synthesis. The invention changes the biochemical parameters of skin treatment by using recombinant YKL-40 proteins produced in mammalian cell lines, which have specific structural characteristics (N-terminal sequence Tyr-Lys-Leu) that enable effective interaction with epithelial cells and keratinocytes, thereby resolving the contradiction between treatment reliability and modulation capability.
2Reliability
If new compounds for modulating terminal differentiation are developed, then treatment efficacy improves, but understanding of physiological mechanisms is still insufficient
Solution Approach 1:
The patent employs feedback mechanisms by utilizing YKL-40 polypeptides that naturally participate in epithelial homeostasis regulation. The recombinant YKL-40 protein provides feedback signals to keratinocytes and epithelial cells that mirror physiological conditions, enabling effective modulation of differentiation while gradually building understanding of the underlying mechanisms through controlled application and observation of effects on terminal differentiation and proteoglycan synthesis.
3Reliability
If YKL-40 polypeptides are used to stimulate terminal differentiation, then skin health improves, but complexity of the treatment composition increases
Solution Approach 1:
The patent applies the extraction principle by isolating and using only the essential YKL-40 polypeptide component (specific amino acid sequences) responsible for stimulating terminal epithelial differentiation and proteoglycan synthesis. By extracting and utilizing this specific protein fragment produced through recombinant DNA technology, the invention simplifies the treatment composition while maintaining high efficacy, avoiding the need for complex mixture of multiple compounds.
Data Source
AI summary
The present invention relates to the use, notably cosmetic and/or therapeutic, of the YKL-40 protein belonging to the family of chitinase-type proteins, of polypeptides derived from this protein or analogs thereof of a nucleic acid sequence encoding such a polypeptide or of an agent that modulates the activity or expression of such a polypeptide notably for stimulation of terminal epithelial differentiation.